Actelion Pharmaceuticals Ltd.
http://www1.actelion.com/en/index.page
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Actelion Pharmaceuticals Ltd.
Cardiac Data Strengthens Capricor’s Duchenne Candidate As FDA Filing Gets Underway
Approval based on the Phase II results could come in early 2025, with a Phase III study already underway.
What GSK’s Depemokimab Will Have To Show In Chronic Rhinosinusitis
Until the full data are released, it is difficult to weigh ANCHOR.
Fusion CEO Talks AZ Deal Making and Canada’s Blossoming Biotech Ecosystem
Fusion Pharmaceuticals Inc CEO John Valliant talked to In Vivo about Canadian leadership in radiopharmaceutical innovation, its differentiated approach, and excitement around combination therapies for precision cancer treatments.
The Anatomy Of Astellas And Poseida's CAR-T Deal
Dealmakers from CAR-T biotech Poseida Therapeutics and Astellas recently sat down with In Vivo to discuss how they reached a $600m deal that combines their technologies and how they plan on moving forward.
Company Information
- Other Names / Subsidiaries
-
- Ceptaris Therapeutics, Inc. (Yaupon Therapeutics, Inc.)
- CoTherix, Inc
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice